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Stellingen
1. The safety profile of liposomal cisplatin shows no benefit over the standard cisplatin 
formulation. (this thesis)
2. At the studied dosage regimen of 175 mg/m2, liposome-entrapped paclitaxel easy-to-use 
is bioequivalent with paclitaxel formulated with polyethoxylated castor oil. (this thesis)
3. Despite promising results in the treatment of cutaneous T-cell lymphoma, histone 
deacetylase inhibitors have not been effective in clinical trials involving solid tumors. (this 
thesis)
4. Not publishing undertaken studies is an omission: sharing these results is essential for 
improving the knowledge necessary for development of future research by the scientific 
community. (this thesis)
5. Patients with mild or moderate hepatic dysfunction can be safely treated with the same 
dose of panobinostat as patients with normal hepatic function. (this thesis)
6. The ultimate goal of the research of drug delivery systems is to prepare a single vial fixed 
dose combination product that encompasses both traditional cytotoxic agents and 
new molecularly targeted modalities with optimum therapeutic effects and acceptable 
toxicity. (Ramsay EC, et al. Curr Drug Deliv 2005;2:341-51)
7. Delivering increased potency at the site of action, while eliminating the toxicities that 
result from off target effects of chemotherapies, is the hope of up-and-coming cancer 
treatments of all kinds. (Sawyers C. Nature 2004;432:294-7)
8. Cancer patients offered phase I trial participation have expectations for treatment benefit 
that exceed those of their physicians. (Meropol NJ, et al. J Clin Oncol 2003;21:2589-96)
9. A fair drug price must reflect the reality of its true benefit and societal and personal costs. 
(Kantarjian HM, et al. J Clin Oncol 2013;31:3600-4)
10. Physicians’ level of confidence may be relatively insensitive to both diagnostic accuracy 
and case difficulty. (Meyer, et al. JAMA Intern Med 2013;173:1952-8)
11. If you look for perfection, you’ll never be content. (Leo Tolstoj, Anna Karenina, 1877)
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